Key benefits of the Randox sPLA₂-IIA reagent
A niche product
The Randox sPLA2-llA mass assay is a niche product from Randox meaning that we are one of the only manufacturers to offer the sPLA2-llA test in an automated biochemistry format
The latex enhanced immunoturbidimetric method delivers exceptional performance and confidence in results
The Randox methodology was compared against other commercially available methods and the Randox sPLA2-llA assay showed a correlation coefficient of r=0.95
Other features of the Randox sPLA₂-IIA reagent
- Liquid ready-to-use reagents for convenience and ease-of-use
- Applications available detailing instrument-specific settings for the convenient use of the Randox sPLA2-llA assay on a wide range of clinical chemistry analysers
- Complementary controls and calibrators available offering a complete testing package
- Automated assay eliminating the inconvenience and time consumption associated with traditional ELISA based testing
- FOR RESEARCH USE ONLY
What is sPLA₂-IIA assay used for?
Biological Significance of sPLA2-llA
The Secretory phospholipase A 2 family comprises a large range of enzymes with their main function being to hydrolyse phospholipids from the cell membrane surface and lipoproteins. sPLA2-llA is already expressed in the arterial wall and its expression is readily up-regulated by inflammatory stimuli. sPLA2-llA is thought to be the most highly expressed of the enzymes with observational studies indicating that higher circulating sPLA2-llA mass is associated with increased risk of incident and major vascular event (MVE). Its association with the production of fatty acids and biologically active phospholipids plays important roles in platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis.
Clinical Significance of sPLA2-llA
sPLA2-llA is a novel cardiac biomarker which acts as a predictor of coronary risk and aids in the prognosis of patients with coronary heart disease (CHD) and cardiovascular events. It is a strong predictor of adverse outcomes, including cardiovascular disease (CVD), myocardial infarction (MI), stroke and heart failure. Unlike traditional cardiac biomarkers used to predict adverse outcomes in patients with acute coronary syndrome (ACS), sPLA2-llA has been shown to act at multiple pathways involved in atherogenesis, from lipid oxidation to modulation of vascular & inflammatory cell activation and apoptosis.